TAMOXIFENS ROLE IN CHEMOPREVENTION OF BREAST-CANCER - AN UPDATE

被引:0
作者
NAYFIELD, SG
机构
关键词
BREAST CANCER; BONE METABOLISM; CHEMOPREVENTION; COLORECTAL CANCER; DNA ADDUCTS;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tamoxifen is an oral antiestrogen first used in metastatic breast cancer in the early 1970s. Large clinical trials were initiated in the late 1970s and early 1980s to test the drug's role as adjuvant therapy in early stage breast cancer. Observations of marked decreases in the development of contralateral breast cancer among tamoxifen recipients suggested potential for the drug in chemoprevention of breast cancer, and a large clinical trial to test the efficacy of tamoxifen in prevention of invasive breast cancer among women at increased risk was implemented in the United States in 1992. This paper reviews the rational for the clinical studies of tamoxifen as a chemopreventive agent for breast cancer and summarizes new information that has contributed to our understanding of tamoxifen's actions at the molecular and clinical levels. Current knowledge about the drug's mechanism of estrogenic and antiestrogenic action and its beneficial effects on blood Lipids and bone metabolism will be presented. Recent research findings about DNA adduct formation and hepatic lesions, tamoxifen-associated gynecologic conditions, and the occurrence of second primary cancers in other organ systems will also be discussed. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:42 / 50
页数:9
相关论文
共 65 条
  • [1] ARRIAGADA R, 1992, P AN M AM SOC CLIN, V11, P52
  • [2] ESTROGEN-RECEPTOR MOLECULAR-BIOLOGY
    BROWN, M
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1994, 8 (01) : 101 - 112
  • [3] TAMOXIFEN - A REAPPRAISAL OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE
    BUCKLEY, MMT
    GOA, KL
    [J]. DRUGS, 1989, 37 (04) : 451 - 490
  • [4] BIOEQUIVALENCE OF 20-MG ONCE-DAILY TAMOXIFEN RELATIVE TO 10-MG TWICE-DAILY TAMOXIFEN REGIMENS FOR BREAST-CANCER
    BUZDAR, AU
    HORTOBAGYI, GN
    FRYE, D
    HO, D
    BOOSER, DJ
    VALERO, V
    HOLMES, FA
    BIRMINGHAM, BK
    BUI, K
    YEH, C
    PLOURDE, PV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) : 50 - 54
  • [5] ULTRASONOGRAPHY SURVEILLANCE OF ENDOMETRIUM IN BREAST-CANCER PATIENTS ON ADJUVANT TAMOXIFEN
    CIATTO, S
    CECCHINI, S
    BONARDI, R
    GRAZZINI, G
    [J]. LANCET, 1994, 344 (8914) : 60 - 60
  • [6] ENDOMETRIAL CHANGES IN POSTMENOPAUSAL WOMEN TREATED WITH TAMOXIFEN FOR BREAST-CANCER
    COHEN, I
    ROSEN, DJD
    SHAPIRA, J
    CORDOBA, M
    GILBOA, S
    ALTARAS, MM
    YIGAEL, D
    BEYTH, Y
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1993, 100 (06): : 567 - 570
  • [7] DALLENBACHHELLW.G, 1992, CURR TOP PATHOL, V85, P1
  • [8] ENDOMETRIAL LESIONS IN PATIENTS UNDERGOING TAMOXIFEN THERAPY
    DEMUYLDER, X
    NEVEN, P
    DESOMER, M
    VANBELLE, Y
    VANDERICK, G
    DEMUYLDER, E
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1991, 36 (02) : 127 - 130
  • [9] LONG-TERM EFFECTS OF TAMOXIFEN ON BLOOD LIPID VALUES IN BREAST-CANCER
    DEWAR, JA
    HOROBIN, JM
    PREECE, PE
    TAVENDALE, R
    TUNSTALLPEDOE, H
    WOOD, RAB
    [J]. BRITISH MEDICAL JOURNAL, 1992, 305 (6847) : 225 - 226
  • [10] EFFECT OF TAMOXIFEN ON SERUM-CHOLESTEROL AND LIPOPROTEINS DURING CHEMOHORMONAL THERAPY
    DNISTRIAN, AM
    SCHWARTZ, MK
    GREENBERG, EJ
    SMITH, CA
    SCHWARTZ, DC
    [J]. CLINICA CHIMICA ACTA, 1993, 223 (1-2) : 43 - 52